A Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Long-term Safety and Tolerability of PF-04950615 in Subjects with Primary Hyperlipidemia or Mixed Dyslipdemia at Risk of Cardiovascular Events

StatusActive
Effective start/end date17/03/1531/03/20

Funding

  • Pfizer, Inc.: $65,572.54

Keywords

  • Biotechnology & Drug Development, Cardiovascular Research